RECURSION
Overview
RECURSION is an AI-driven drug discovery and development platform developed by Recursion Pharmaceuticals, a clinical-stage TechBio company. The platform, known as the Recursion OS, integrates automated experimental biology, high-content imaging, machine learning, and computational chemistry. It is designed to accelerate the identification of novel drug targets and the design of optimized molecules.
The tool is primarily for researchers and pharmaceutical companies involved in drug discovery and early development, particularly in areas of high unmet medical need such as oncology and rare diseases. Recursion itself is advancing an internal pipeline of drug candidates and collaborates with larger pharmaceutical companies.
Within a research and development workflow, RECURSION aims to industrialize drug discovery by generating and analyzing massive proprietary biological and chemical datasets. This involves conducting millions of wet lab experiments weekly using robotics and computer vision, with the results feeding back into the Recursion OS for continuous improvement. The platform leverages machine learning models and large language models to uncover biological and chemical insights.
Notable capabilities include the ability to identify novel disease targets and precision-design drug candidates. The Recursion OS has been used to accelerate the timeline from target identification to Investigational New Drug (IND)-enabling studies. The company also utilizes its platform to support clinical trial workflows, for example, by creating real-time clinical monitoring portals to expedite dose escalation meetings. Recursion has developed BioHive-2, a powerful supercomputer, to process its extensive data.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-native, end-to-end drug discovery and development platform (Recursion OS)
- Integration of machine learning, automation, and biological experimentation
- Proprietary biological and chemical datasets (>50 petabytes)
- Automated wet lab capable of millions of cell experiments per week
- BioHive-2 supercomputer (in collaboration with NVIDIA)
- Large language model (LLM) LOWE for workflow orchestration
- Pipeline of potential first-in-class and best-in-class treatments
- Strategic partnerships with pharmaceutical and technology leaders
- Phenomic, transcriptomic, proteomic, and ADME data integration
- Identification of novel drug targets and optimized molecules
Use Cases
- Accelerating drug discovery and development
- Identifying novel therapeutic targets for various diseases
- Developing treatments for aggressive cancers
- Developing treatments for rare diseases
- Optimizing clinical trials
- Drug repurposing
What Physicians Need to Know
Physicians should be aware that Recursion's platform is primarily focused on the early stages of drug discovery, specifically target identification and lead optimization, by leveraging AI and automation to accelerate the discovery of new medicines. While not directly involved in clinical trial matching or real-world evidence analysis in a patient-facing capacity, their work aims to bring more effective therapies to clinical trials faster. Understanding the AI-driven approach to target identification can provide insight into the rationale behind novel therapeutic candidates emerging from their pipeline.
Recursion's platform, the Recursion OS, is an integrated system that combines in-house automated wet-labs with a computational drug discovery platform. This allows for seamless integration of experimental data generation and AI-driven analysis within their own ecosystem. They have also formed strategic collaborations, such as with NVIDIA, to further enhance their AI models and accelerate drug discovery, indicating a focus on integrating advanced computational capabilities and potentially external data sources into their platform.
Details
| Category | Drug Discovery & Research |
| Pricing | Contact for pricing |
| Deployment | Cloud-based |
| Compliance | |
| BAA Available | Unknown |
| HIPAA Compliant | Unknown |
| FDA Status | Cleared AI-estimated |
| Integrations | |
| EHR | Not specified |
| Specialties | Infectious Disease, Neurology, Oncology |
What the Web Says
Recursion (Recursion.com) is a TechBio company that utilizes artificial intelligence and automated laboratories to accelerate drug discovery and development, focusing on oncology and rare diseases. The company aims to industrialize drug discovery by generating massive biological and chemical data to train machine learning algorithms, predicting experimental outcomes, and reducing the time and cost of early-stage drug discovery. While they have several programs in clinical trials and strategic partnerships with pharmaceutical and technology leaders, some opinions suggest that the company's ambitious approach carries significant financial risks and that real product revenue is still years away.
Overall: MixedStrengths
- Utilizes AI and automated labs to accelerate drug discovery, potentially reducing time and cost.
- Has a growing pipeline of potential therapies for oncology and rare diseases.
- Strategic partnerships with major pharmaceutical companies like Roche/Genentech and Sanofi, and technology leaders like NVIDIA.
- Mission-driven organization with a strong culture among some employees.
- Offers generous benefits and pay to employees.
- CEO is transparent and a good speaker, with lots of progress on the company's vision.
Limitations
- High-risk, speculative bet on the future of science with significant cash burn and real product revenue years out.
- Concerns about job security and advancement, with reports of massive layoffs and poor management.
- Work-life balance is often poor, with demands for unpaid overtime.
- Some employees describe the company culture as immature, with poor leadership and a fear of expressing disagreement.
- Efficacy evaluations for some lead experimental drugs have been unclear, despite meeting safety goals.
- The technology's effectiveness in revolutionizing drug development from the ground up is questioned by some, with concerns about overestimating the company's abilities.
Based on reviews from: Reddit, Indeed.com, Slashdot, Investing.com, MarketBeat, BioPharma Dive, YouTube, G2
Last updated: 2026-09-22
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate RECURSION
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for RECURSION.
Recursion Pharmaceuticals CEO Chris Gibson goes one-on-one with Jim Cramer
CNBC Television
Recursion CEO on $688M Exscientia acquisition: Hope to bring better medicines to patients sooner
CNBC Television
Recursion Thinks AI Can Lower The High Failure Rate Of New Pharmaceutical Drugs
Forbes
Lightning Round: Recursion Pharmaceuticals and NuScale Power
CNBC Television
Lightning Round: Recursion Pharma is now a meme stock, says Jim Cramer
CNBC Television
The Identity Crisis of Recursion Pharmaceuticals, RXRX
Future Ready
Frequently Asked Questions
Investors who backed RECURSION
Funded through the company that built this tool.
